KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by First Turn Management LLC

First Turn Management LLC lessened its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 66.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 355,000 shares of the specialty pharmaceutical company's stock after selling 704,540 shares during the period. First Turn Management LLC owned 0.82% of KalVista Pharmaceuticals worth $4,111,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. BNP Paribas Financial Markets raised its stake in KalVista Pharmaceuticals by 94.5% during the first quarter. BNP Paribas Financial Markets now owns 18,013 shares of the specialty pharmaceutical company's stock worth $214,000 after purchasing an additional 8,750 shares during the period. StemPoint Capital LP raised its position in shares of KalVista Pharmaceuticals by 174.4% during the 1st quarter. StemPoint Capital LP now owns 1,161,060 shares of the specialty pharmaceutical company's stock valued at $13,770,000 after buying an additional 737,886 shares during the period. EntryPoint Capital LLC acquired a new position in KalVista Pharmaceuticals in the first quarter valued at approximately $92,000. Capital World Investors purchased a new position in KalVista Pharmaceuticals in the first quarter worth approximately $17,370,000. Finally, PEAK6 Investments LLC acquired a new stake in KalVista Pharmaceuticals during the first quarter worth $178,000.

KalVista Pharmaceuticals Stock Down 2.7 %

NASDAQ:KALV traded down $0.25 during trading hours on Tuesday, reaching $9.05. 479,586 shares of the stock were exchanged, compared to its average volume of 484,232. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.39 and a twelve month high of $16.88. The business has a 50-day moving average of $11.10 and a two-hundred day moving average of $12.03. The company has a market capitalization of $391.14 million, a price-to-earnings ratio of -2.56 and a beta of 0.92.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.04. On average, research analysts forecast that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current fiscal year.

Insider Activity

In related news, CEO Benjamin L. Palleiko sold 7,352 shares of the business's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $12.19, for a total transaction of $89,620.88. Following the completion of the transaction, the chief executive officer now directly owns 250,800 shares of the company's stock, valued at $3,057,252. The trade was a 2.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Paul K. Audhya sold 2,135 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $12.40, for a total value of $26,474.00. Following the completion of the sale, the insider now directly owns 83,745 shares in the company, valued at $1,038,438. This represents a 2.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 10.50% of the company's stock.

Analyst Upgrades and Downgrades

KALV has been the topic of several recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Monday, October 7th.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).